Nanocurcumin: Why It Matters, The Complete Evidence Guide. NanoCur education series card showing an amphipathic carrier micelle surrounded by water molecules.

Nanocurcumin: Why It Matters

By Michael Centola, Ph.D. (Chief Executive Officer & Chief Scientific Officer, Haus Bioceuticals, Inc.; ORCID · Google Scholar) and Philip Alex, M.D., Ph.D. (Co-Founder & Chief Medical Officer, Haus Bioceuticals, Inc.; PubMed)

Definition

Nanocurcumin is a set of nanoscale curcumin–carrier complexes, roughly 1 to 100 nanometers in size, that increase curcumin’s water solubility, absorption, and activity.

Summary

Built on state-of-the-art pharmaceutical and materials science, these advanced delivery systems have solved the problem that held curcumin back for half a century: a potent bioactive molecule the body could not absorb4,5,6. Nanocurcumin delivery systems have fundamentally changed the curcumin field, fueling a growing body of in vitro, preclinical, and clinical studies demonstrating curcumin's activity in a wide range of clinical settings and refining our understanding of the molecular mechanisms behind these activities40,41,42.

This article provides a summary of the nanocurcumin field and a comprehensive annotated collection of the nanocurcumin peer-reviewed literature to date for further research. In it, we:

  • Review what nanocurcumin is and why these delivery systems govern what curcumin can do (Figure 2 →)
  • Catalog today's commercial and experimental nanocurcumin delivery systems (Table 1 →)
  • Summarize the head-to-head peer-reviewed literature comparing nanocurcumin with other curcumin forms, all of which demonstrated the advantages of these advanced delivery systems (Table 2 →)
  • Close with an annotated library of 101 peer-reviewed publications across 9 research domains, each with a plain-English summary and a direct link to the source (Library →)

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Curcumin Is Really 3 Related Molecules That Are Poorly Absorbed

What is commonly called, and what is referred to in this article as "curcumin," is, chemically speaking, a family of 3 very closely related bioactive curcuminoid molecules from turmeric: curcumin, demethoxycurcumin, and bisdemethoxycurcumin (Fig. 1). The 3 curcuminoids differ only by a few atoms and have similar molecular mechanisms and clinical effects. Interestingly, studies attempting to distinguish the 3 molecules' clinical activity and mechanisms of action have produced conflicting findings, with the rank order of activity on some endpoints changing from study to study, suggesting their activities may be more similar than any single study indicates9,10,11. Importantly, the 3 curcuminoids copurify when extracted from turmeric, so all commercial curcumin brands contain, and most scientific studies are run on, purified extracts with all 3, in roughly 70:20:10 proportions12,13. Most relevant to this article, curcuminoids are practically insoluble in water, and what cannot dissolve mostly cannot be absorbed, so even at massive doses (up to 10 grams daily, roughly a handful of powder) only trace amounts are found in blood3,4. Also, curcuminoids are the most bioactive components of turmeric, but make up only about 1–3% of turmeric powder by weight1. This is why the evidence in this article supports the recommendation to use curcumin brands that use some form of advanced delivery system and contain 95% or greater curcuminoid extracts, not turmeric powder.

The three curcuminoids of turmeric — curcumin, demethoxycurcumin, and bisdemethoxycurcumin — differ only in their methoxy groups; curcuminoids are 1–3% of turmeric powder in a roughly 70:20:10 mix; curcumin is practically insoluble in water.
Figure 1 · What “curcumin” actually is: three closely related molecules, a tiny fraction of turmeric, and a solubility problem.
The three curcuminoids of turmeric — curcumin, demethoxycurcumin, and bisdemethoxycurcumin — differ only in their methoxy groups; curcuminoids are 1–3% of turmeric powder in a roughly 70:20:10 mix; curcumin is practically insoluble in water.
Figure 1 · What “curcumin” actually is: three closely related molecules, a tiny fraction of turmeric, and a solubility problem.

Commercial and Experimental Nanocurcumin Delivery Systems

Nanocurcumin is a set of nanoscale curcumin–carrier complexes, roughly 1 to 100 nanometers in size, that increase curcumin's water solubility, absorption, and activity. The carriers are amphipathic: one part is charged (hydrophilic/water-loving), so it dissolves in water, and one part uncharged (hydrophobic/water-fearing) which binds to the similarly hydrophobic curcumin. At this time 3 families of nanocurcumin delivery systems dominate the field5,6: lipid-based systems (liposomes, solid lipid nanoparticles, nanoemulsions), polymer-based systems (biodegradable nanoparticles, micelles, nanogels), and molecular inclusion complexes (e.g. cyclodextrins, ring-shaped nonmetabolizable sugar molecules with a curcumin-sized pocket, which form complexes at the smallest end of the scale)7,8 (Figure 2 →).

A comprehensive compendium of nanocurcumin formulations is presented in Table 1, divided into "Commercial Brands," available for sale either currently or in the past, and "Experimental Formulations," described in the literature but not available for sale at the time of this writing (Table 1 →).

What nanocurcumin is and how it works: an amphipathic carrier with a water-loving (hydrophilic/charged) surface and a water-fearing (hydrophobic) core that binds curcumin (Panel A); the three delivery-system families — lipid-based, polymer-based, and molecular inclusion complexes such as NanoCur's ~5 nm plant-based β-cyclodextrin (Panel B); and formulations from Table 1 on a logarithmic nanometer ruler with the 1–100 nm nanoscale window marked (Panel C).
Figure 2 · What nanocurcumin is and how it works: the amphipathic mechanism (A), the three carrier families (B), and the formulation landscape on a nanometer ruler (C).
What nanocurcumin is and how it works: an amphipathic carrier with a water-loving (hydrophilic/charged) surface and a water-fearing (hydrophobic) core that binds curcumin (Panel A); the three delivery-system families — lipid-based, polymer-based, and molecular inclusion complexes such as NanoCur's ~5 nm plant-based β-cyclodextrin (Panel B); and formulations from Table 1 on a logarithmic nanometer ruler with the 1–100 nm nanoscale window marked (Panel C).
Figure 2 · What nanocurcumin is and how it works: the amphipathic mechanism (A), the three carrier families (B), and the formulation landscape on a nanometer ruler (C).

Table 1. A Compendium of Nanocurcumin Formulations

A. Commercial Brands

Formulation / example Carrier technology Reported size Human evidence Notes & sources
NanoCur® (Haus Bioceuticals) Plant-based β-cyclodextrin molecular inclusion complex ~5 nm molecular complex Blinded preclinical head-to-heads; human studies as R&D provenance — see The Science Piperine-free; patent pending — published applications WO2023023648A1, US20240350660A1
Qunol® Extra Strength Turmeric γ-cyclodextrin inclusion complex (per manufacturer)14 Molecular complex; product size not published Carrier-class PK: γ-CD complex ~39× total curcuminoids vs. unformulated15 Class-level evidence — this brand’s finished product not independently assessed
Cavacurmin® (ingredient in several retail brands) γ-cyclodextrin inclusion complex Molecular complex ~39× total curcuminoids15; tetrahydrocurcumin exposure16 Industry-conducted studies
SinaCurcumin® (Exir Nano Sina, Iran) Polymeric nanomicelle 9.5 ± 0.1 nm by DLS, peer-reviewed17 Multiple published human trials of the nanomicelle format6 Size now peer-review-characterized — a model of the transparency this table rewards
BioCurc® Liquid-droplet micellar (Gelucire® + polysorbate 20)19 Nano-micellar; nm figure not published ~522× dose-normalized AUC/mg vs. 95% curcumin18 The largest published fold-figure — and the reason fold-figures aren’t rankable (see note)
NovaSOL® (ingredient; retail: Solgar® Full Spectrum, curcumin-Loges®) Liquid polysorbate micelle Micellar; size not published ~185× AUC vs. native curcumin20; free-curcumin caveat21 Best-studied micellar ingredient, two independent human PK datasets20,21
SNEC30 (Arbro Pharmaceuticals, India) Self-nanoemulsifying delivery system (SNEDDS) Droplet size not published Manufacturer-claimed trials; not independently verified on PubMed India’s Govt.-DST-supported entry; only commercial SNEDDS example verified
CumarGold® (CVI Pharma, Vietnam) Nano curcumin dispersion 30–50 nm — manufacturer claim only None located on PubMed Vietnam’s leading nano-curcumin brand; all figures manufacturer-reported
Liposomal curcumin retail lines (e.g., lipolife®, Actinovo) Phospholipid liposomes Finished-product sizes generally not disclosed Category pattern: marketing claims without published PK identifiers Included as a category; ask any liposomal brand for its measured size
Theracurmin® Colloidal submicron dispersion (wet-milled, gum-stabilized) Mean 0.19 µm (190 nm)22 Human PK studies22,23 Above 100 nm; included at the definitional boundary

B. Experimental Formulations

Formulation / example Carrier technology Reported size Evidence stage Notes & sources
NanoCurc™ (academic) Polymeric nanoparticle (NIPAAM copolymer) ~50 nm Preclinical program (cancer, liver, neuro models) The 2007 formulation whose paper coined the term “nanocurcumin”24
Lipocurc™ (intravenous) Liposome ~100 nm class Human Phase I: healthy volunteers25; dose-escalation in cancer patients26 The furthest-advanced IV program; not an oral supplement
PLGA polymeric nanoparticles Biodegradable polymer NP ~200 nm27; 264 nm28 Preclinical: ~5.6× oral bioavailability (rat)27; ≥9-fold vs. curcumin+piperine28 The research standard-bearer
Alginate–polysorbate nanoparticle Polysaccharide NP 383 nm Human: ~5× oral bioavailability in healthy volunteers29 One of the few experimental systems with human data
Solid lipid nanoparticles / NLCs Lipid matrix particles ~100–200 nm typical Preclinical / in vitro Protected gastric transit; reviewed in5,6
Nanoemulsions Oil-in-water droplets ~150–300 nm Preclinical / in vitro Food-science workhorse
Nanocrystals / nanosuspensions Carrier-free milled curcumin Sub-micron Preclinical Pure-curcumin route, no excipient
Emerging architectures (polymeric micelles ~20–25 nm; dendrimer hybrids 40–80 nm; nanogels ~170 nm; protein/silk NPs <200 nm; niosomes; cyclodextrin nanosponges; exosomes) Various Tens–hundreds of nm In vitro, early preclinical The research frontier; class reviews5,6

Table 1 footnotes. 1. Fold-increases in absorption are independent measures from different studies, under idiosyncratic conditions (different comparators, doses, analytical methods, and so on), so they cannot be ranked relative to each other21. 2. Where a specific brand’s finished product has not itself been characterized or clinically assessed, the evidence shown is for its carrier class. 3. Sizes and technologies are as disclosed by the manufacturer or reported in the cited literature. Inclusion is not endorsement; trademarks belong to their owners.

Advanced delivery that is not nanoscale. For completeness: several well-known, well-researched formulations improve curcumin's water solubility, absorption, and activity without being nanoscale, and they represent a different category than the nanocurcumin formulations described above. This includes phospholipid complexes (Meriva®36), solid-lipid particle matrices (Longvida®37), hydrophilic-carrier dispersions (CurcuWIN®38), turmeric-essential-oil formulations (BCM-95®35), fenugreek-fiber matrices (CurQfen®), cold-water dispersion coatings (HydroCurc®39), dried colloidal suspensions (TurmiPure Gold®33), polar-resin dispersions (Curcugen®), whole-matrix formulations (Cureit™), amorphous solid dispersions (curcuRouge®/Curalieve®, Theracurmin Super®), and micronized matrices that disclose their micron scale outright (MicroActive®, <10 µm by its own specification). Different chemistry, sometimes strong absorption data, but a different category than the nanoscale systems above, which is exactly why a characterized size tells you more than the word "nano."

Nanocurcumin Outperforms Other Curcumin Forms in Head-to-Head Studies

Every published head-to-head study that has directly compared nanocurcumin with another curcumin form, whether standard curcumin, curcumin + black pepper extract, or an enhanced non-nano formulation, has shown the same result: the nanocurcumin formulation performed better. That comparison has been made in only 21 published controlled comparator studies, studies that provide an accurate measure by making the comparison within a single trial, in the same study cohort, with the same outcomes measured. They comprise 8 human pharmacokinetic studies, which measure absorption; 2 human clinical trials, which measure biomarker outcomes; 10 preclinical studies in animal models; and 1 meta-analysis pooling 72 animal studies. Each study is presented with the comparators measured and its key finding (Table 2).

Table 2. Outcomes of Nanocurcumin Controlled Comparator Studies

A. Pharmacokinetic studies

Eight human crossover studies have measured curcumin absorption from different formulations in the same subjects. The delivery-engineered formulation produced the highest exposure in all eight.

Study Comparison Finding
Sasaki 201148 Colloidal nanoparticle (Theracurmin) vs. curcumin powder at the identical 30 mg dose, crossover At the same dose, the nanoparticle form delivered 27-fold higher exposure (AUC 113.0 vs. 4.1 ng·h/mL) and roughly 16-fold higher peak levels (29.5 vs. 1.8 ng/mL)
Schiborr 201420 Micellar curcumin vs. micronized vs. native, 23 adults Micelles delivered ~185-fold more total curcumin than native (277-fold in women, 114-fold in men), with all safety parameters in the normal range
Sunagawa 201544 Submicron colloidal (Theracurmin) vs. turmeric-oil (BCM-95) vs. phospholipid (Meriva) The colloidal formulation delivered 11-fold and 4.6-fold more curcumin over 24 hours, despite its capsules containing measurably less curcumin (182 vs. 279 mg)
Purpura 201815 γ-cyclodextrin complex vs. unformulated extract vs. phytosome vs. turmeric-essential-oil formulation The cyclodextrin complex delivered ~39-fold higher dose-normalized total-curcuminoid exposure, even though the unformulated comparator was dosed roughly five times higher
Flory 202132 Eight formulations in one trial, including liposomal, phytosome, turmeric-oil, submicron-particle, and piperine comparators Only two arms significantly exceeded native curcumin: micellar, 57-fold, and γ-cyclodextrin, 30-fold. The piperine arm’s exposure was essentially identical to plain curcumin
Fança-Berthon 202133 Five formulations, including a piperine-curcuminoid combination Per milligram dosed, micellar delivered ~37 times and dried-colloidal ~20 times the exposure of standard extract. The piperine combination did not differ from standard extract
Thanawala 202434 Water-dispersible formulation, 250 mg, vs. curcuminoids + piperine, 1,500 mg The engineered formulation produced higher peak levels (74.6 vs. 22.8 ng/mL) at one-sixth the material
Kroon 202521 Five commercial products, including solid-lipid and piperine formulations, with and without added piperine “Piperine addition provided no benefit.” Free curcumin stayed near the detection floor in every product, and quadrupling the dose did not raise it

B. Clinical studies

Two human trials have compared formulations head-to-head on clinical biomarkers.

Study Comparison Finding
Helli 202145 Curcumin nanomicelle 80 mg/day vs. native curcumin 500 mg/day vs. placebo; 90 coronary-angioplasty patients, 8 weeks Both curcumin groups improved lipid, oxidative-stress, and inflammatory markers versus placebo; the nanomicelle outperformed native curcumin on five endpoints (total cholesterol, triglycerides, SOD, MDA, TNF-α) at about one-sixth the dose¹
Grafeneder 202246 Micellar vs. native curcumin, crossover; 15 healthy adults, 7 days Confirmed the absorption advantage within the trial; no short-term change in stimulated inflammatory markers with either formulation²

C. Preclinical studies

Animal studies report the same direction, and in volume.

Study Comparison Finding
Shaikh 200928 Polymeric nanoparticle vs. curcumin + piperine (rat, oral) 9.2-fold higher oral bioavailability at less than half the dose³
Zhang 202647 Meta-analysis of 72 animal fatty-liver studies: delivery systems vs. native curcumin Delivery-system curcumin significantly outperformed native curcumin on efficacy outcomes
Four equal-dose comparisons49,50,51,52 Nanocurcumin vs. curcumin at the same dose, in models of chemical liver injury, arsenic toxicity, copper neurotoxicity, and diabetes The nano form produced greater protection in all four models
Four low-dose comparisons53,54,55,56 Nanocurcumin at 4- to 25-fold lower doses, in models of cerebral malaria, muscle repair, reproductive injury, and lung toxicity Matched or exceeded conventional curcumin in all four models⁴
Elbassiouni 202257 Curcumin-loaded PLGA nanoparticles vs. curcumin, colon model Restored inflammatory markers several-fold more effectively than conventional curcumin

Table 2 footnotes. 1. Endpoints on which the 80 mg nanomicelle outperformed 500 mg native curcumin: total cholesterol, triglycerides, the antioxidant enzyme SOD, the oxidative-damage marker MDA, and the inflammatory cytokine TNF-α45. 2. An expected result over seven days in healthy subjects; a ~10% PCSK9 reduction appeared only with the micellar form but did not replicate in a second cohort46. 3. The study that framed this comparison for the field: nanoparticle curcumin outperformed the black-pepper strategy while receiving less than half the curcumin28. 4. In the cerebral-malaria model, the nanocurcumin also delivered 3- to 4-fold higher brain levels at a 15-fold lower dose53. These studies compare specific products, not whole classes, and most measure absorption rather than clinical outcomes; higher absorption is the means to activity, not proof of it. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.

The 4 Key Reasons Why Black Pepper Extract Fails in Head-to-Head Testing

For decades, supplement labels, health blogs, and influencer videos have repeated a talking point built on one unreplicated study, a claim that multiple controlled comparative studies have now directly contradicted30. The head-to-head comparator studies summarized above demonstrate that nanocurcumin delivery systems outperform black pepper + curcumin formulations, and, crucially, that black pepper + curcumin formulations perform nearly identically to standard curcumin alone32,33,21,34,28. Equally telling for a question at the center of a multi-billion-dollar category: none of these comparator studies was run by a black-pepper-extract brand; all were run by non-commercial research groups. Because the erroneous messaging is so pervasive, the 4 key reasons why black pepper extract falls short, and why confusion persists, are summarized below. For a more detailed analysis, see the dedicated review on this site: It's Time to Reassess Piperine and Curcumin: The Evidence Doesn't Support What You've Been Told →

  1. The 1998 industry-sponsored study could not distinguish active from inactive curcumin, and nearly all of what it measured was inactive metabolites. The one and only study reporting a 2,000% boost in curcumin absorption from black pepper extract was an industry-sponsored study that used an assay that did not distinguish between active free curcumin and inactive curcumin metabolites in blood30. As subsequent studies using methods that can distinguish these two forms have shown, the vast majority of what such assays measure is the inactive conjugate pool rather than active curcumin21.
  2. All subsequent studies of the effects of black pepper extract found no meaningful increase in active curcumin in blood. When independent groups at Tufts, Hohenheim, Amsterdam UMC, and elsewhere repeated the piperine experiment using liquid chromatography–mass spectrometry that measures free curcumin separately from its conjugates, all four studies found that adding piperine produced no meaningful increase in free curcumin, which remained essentially undetectable, below about 2 nanomolar, even with high-dose piperine58,32,33,21.
  3. The body routes around piperine's enzyme blockade. Piperine inhibits specific phase-II enzymes (UGT and SULT families), but human first-pass metabolism is massively redundant: when glucuronidation slows, curcumin is routed through alternative pathways, including phase-I reductases that rapidly convert it to reductive metabolites such as tetrahydrocurcumin, so free curcumin still fails to accumulate in the bloodstream31,21.
  4. Head-to-head clinical outcomes show no added benefit of black pepper extracts, and some added issues. In randomized trials and meta-analyses that directly compared curcumin + piperine against curcumin alone, the combination failed to show superior clinical endpoints: in a 15-trial meta-analysis in fatty-liver disease, curcumin alone significantly reduced the liver enzymes ALT and AST while the curcumin-piperine combination moved neither59; and in the one three-arm trial that tracked tolerability, the piperine combination reported four times more heartburn than the other groups, detailed in It's Time to Reassess Piperine and Curcumin →
Two roads to absorption: nanocurcumin dissolves curcumin directly and is absorbed with no drug-metabolism enzymes involved, while black pepper extract leaves curcumin insoluble and blocks clearance enzymes, with free curcumin remaining below 2 nanomolar and a drug-interaction risk.
Figure 3 · Two roads to absorption: direct solubility vs. enzyme inhibition.
Two roads to absorption: nanocurcumin dissolves curcumin directly and is absorbed with no drug-metabolism enzymes involved, while black pepper extract leaves curcumin insoluble and blocks clearance enzymes, with free curcumin remaining below 2 nanomolar and a drug-interaction risk.
Figure 3 · Two roads to absorption: direct solubility vs. enzyme inhibition.

What the New Delivery Systems Are Changing That Is Not Commonly Reported

Curcumin's clinical benefits are obscured by the roughly 50 years of literature testing a compound that barely reached the study subjects swallowing it, and by the common misconception that black pepper extracts are more impactful than the literature now demonstrates. Nanocurcumin delivery systems improve curcumin's solubility directly. Consequently, the curcumin field is shifting away from turning off the body's natural liver defense enzymes, an approach that also carries real medication-interaction risks, and toward a more evidence-based approach to increasing curcumin activity. The result is a growing body of literature demonstrating curcumin's potential across a wide range of clinical settings. Unfortunately, when self-proclaimed expert influencers discuss the topic, they often miss this distinction: they tend to lump studies of advanced delivery systems together with studies of curcumin–black-pepper formulations and standard curcumin, and then report that the field is inconsistent, or that curcumin's effect is more limited than the nanocurcumin literature demonstrates.

Choosing Well, Whatever Brand You Buy

Five questions separate engineered formulations from label decoration. Is it purified curcumin (95%+ curcuminoids), not ground turmeric root powder? Is the delivery system named and well characterized, cyclodextrin, micelle, liposome, and not just misusing a scientific term like "nano"? Does it achieve absorption without piperine's enzyme-inhibition mechanism? Is it independently tested, with certificates of analysis43? And is there evidence beyond a blood-level number? Since fold-increase figures from different studies cannot be compared21, favor brands that can point to measured activity for their actual formulation.

Where NanoCur® Fits In

NanoCur® is the culmination of 15 years of pharmaceutical R&D. Unlike any other program we are aware of, our program selected for optimized curcumin activity, not just absorption. The studies concluded when we identified a nanocurcumin formulation in preclinical head-to-head testing against top-selling brands →, which had higher activity and was more affordable. We refer to NanoCur as a pharma-grade curcumin because the R&D process we utilized is the same rigorous scientific method used to optimize pharmaceutical drug delivery. Moreover, our patent-pending formulation, curcumin complexed to the plant-based nanocarrier β-cyclodextrin, pushed the boundaries of what was possible using state-of-the-art natural medicine principles. Every batch is 3rd-party tested by an independent lab →.

Common Questions

What is nanocurcumin? Nanocurcumin is a set of nanoscale curcumin–carrier complexes, roughly 1 to 100 nanometers in size, that increase curcumin's water solubility, absorption, and activity. The term is used loosely in the market, so look for a named carrier technology and a characterized size.

Why does nanocurcumin matter? Because standard curcumin barely absorbs, decades of curcumin's promise were locked behind a solubility barrier. Nanoscale delivery systems removed that barrier, changing both what supplements can deliver and what research can test.

Is nanocurcumin the same as turmeric or curcumin? No. Turmeric is the whole root powder (~1–3% curcuminoids); curcumin is the purified active fraction; nanocurcumin is purified curcumin engineered into a delivery system that the body can actually absorb.

Does nanocurcumin need black pepper extract? No. Piperine inhibits the enzymes that clear curcumin, and in recent independent studies did not measurably raise curcumin uptake. Nanoscale delivery works directly, through solubility, and demonstrated superior absorption in head-to-head studies vs. black pepper extract.

Has nanocurcumin been tested head-to-head against regular curcumin or black pepper formulas? Yes. Eight human crossover studies have directly compared formulations in the same subjects, and the delivery-engineered formulation out-absorbed its comparators in all of them, while black pepper (piperine) arms added no measurable benefit in any trial that included one. In the one clinical head-to-head, an 80 mg nanomicelle outperformed 500 mg of standard curcumin on five biomarkers of lipids, oxidative stress, and inflammation.

Is everything labeled "nano" really nanoscale? No. Some well-known enhanced-absorption products are sub-micron or micron-scale by their own published data. A characterized particle size tells you more than the word "nano."

Is nanocurcumin safe? Curcumin is generally well tolerated in trials. Anyone taking prescription medications, particularly blood thinners, statins, immunosuppressants, or chemotherapy, should talk with their clinician before using any curcumin product.

Related Reading

It’s Time to Reassess Piperine and Curcumin →
Curcumin vs. Turmeric: What’s the Difference? →
The Science Behind NanoCur — 15 Years, Three Generations →
Independent Third-Party Testing →

An Annotated Nanocurcumin Library

The nanocurcumin literature is extensive and bridges multiple scientific domains. To help make sense of it we created an annotated bibliography of 101 peer-reviewed publications, divided into 9 scientific domains. Each article includes a one-to-two-sentence plain-English annotation and an evidence-type tag. Each annotation is linked to the primary literature. Entries also cited in the article above are marked with an R and a number referencing their position in the article's reference list.

Domain A: Curcumin fundamentals & pharmacokinetics

1. Anand P, et al. Bioavailability of curcumin: problems and promises. Mol Pharm. 2007.Review
The field-defining review that spelled out why curcumin barely reaches the blood (poor solubility, chemical instability, rapid metabolism, fast elimination) and catalogued the formulation strategies meant to fix each. PubMed Cited in this article as reference 4.
2. Hewlings SJ, Kalman DS. Curcumin: a review of its effects on human health. Foods. 2017.Review
A broad, accessible primer on what curcumin is and the human-health domains it has been studied in, commonly used as an entry point to the compound. PubMed Cited in this article as reference 2.
3. Sharma RA, et al. Phase I clinical trial of oral curcumin. Clin Cancer Res. 2004.Human PK
An early human dose-escalation trial showing that even multi-gram daily oral doses yield only trace plasma curcumin, establishing the absorption ceiling that drives the whole delivery field. PubMed Cited in this article as reference 3.
4. Storka A, et al. Safety, tolerability and pharmacokinetics of liposomal curcumin in healthy humans. Int J Clin Pharmacol Ther. 2015.Human PK
An intravenous-dosing study in which parent curcumin and its early metabolites fell below detectable levels within about an hour: the body clears curcumin fast even when absorption is bypassed. PubMed Cited in this article as reference 25.
5. Hassanzadeh K, et al. Obstacles against the marketing of curcumin as a drug. Int J Mol Sci. 2020.Review
A review cataloguing the drug-development hurdles of instability, heavy metabolism, and the gap between lab activity and clinical proof that keep curcumin from qualifying as a medicine. PubMed
6. Lin JK, et al. Recent studies on the biofunctions and biotransformations of curcumin. Biofactors. 2000.Review
An early mechanistic review describing how the body chemically transforms curcumin through conjugation and reduction. PubMed
7. Tayyem RF, et al. Curcumin content of turmeric and curry powders. Nutr Cancer. 2006.Chemistry
An analytical measurement finding curcuminoids make up only a low single-digit percentage of turmeric powder, the quantitative basis for separating whole turmeric from concentrated extract. PubMed Cited in this article as reference 1.
8. Jayaprakasha GK, et al. Improved HPLC method for determination of the three curcuminoids. J Agric Food Chem. 2002.Chemistry
Establishes that commercial "curcumin" is a three-curcuminoid mixture and quantifies each across turmeric varieties. PubMed Cited in this article as reference 12.
9. Pan Y, et al. Separation of three curcuminoids by countercurrent chromatography. J Sep Sci. 2020.Chemistry
A modern isolation study whose recovered proportions (~71:19:10) put concrete numbers on the typical curcumin : demethoxycurcumin : bisdemethoxycurcumin ratio. PubMed Cited in this article as reference 13.
10. Sandur SK, et al. Curcuminoids and turmerones differentially regulate anti-inflammatory and anti-proliferative responses. Carcinogenesis. 2007.In vitro
The key comparative study: the three curcuminoids share activities but rank differently by endpoint: anti-inflammatory potency tracks the methoxy groups, while anti-proliferative potency is comparable. PubMed Cited in this article as reference 9.
11. Sreejayan N, Rao MN. Free radical scavenging activity of curcuminoids. Arzneimittelforschung. 1996.In vitro
Early structure-activity work showing the phenolic and methoxy groups drive radical-scavenging, ranking curcumin > demethoxy > bisdemethoxy. PubMed Cited in this article as reference 10.
12. Kalaycıoğlu Z, et al. Comparison of antioxidant, anticholinesterase, and antidiabetic activities of the three curcuminoids. Nat Prod Res. 2017.In vitro
Shows the activity ranking reverses by endpoint, with bisdemethoxycurcumin winning on some enzyme targets, cementing "similar but not identical." PubMed Cited in this article as reference 11.

Domain B: Delivery-system science

13. Karthikeyan A, et al. Nanocurcumin: a promising candidate for therapeutic applications. Front Pharmacol. 2020.Review
A survey of the major nanocarrier classes built for curcumin and the therapeutic areas where nano-formulation has been explored. PubMed Cited in this article as reference 6.
14. Tabanelli R, et al. Improving curcumin bioavailability: current strategies and future perspectives. Pharmaceutics. 2021.Review
A structured overview of solubility-, absorption-, and stability-boosting approaches that weighs what each achieves and where the evidence stays thin. PubMed
15. Ipar VS, et al. Enhancing curcumin oral bioavailability through nanoformulations. Eur J Drug Metab Pharmacokinet. 2019.Review
Classifies delivery systems and argues directly that "fold-increase" absorption figures are measured too differently to be ranked against one another. PubMed
16. Jacob S, et al. Advances in nanocarrier systems for curcumin. Nanomaterials. 2024.Review
An up-to-date survey of nanocarrier engineering noting most head-to-head efficacy evidence remains preclinical. PubMed Cited in this article as reference 5.
17. Mahjoob M, Stochaj U. Curcumin nanoformulations to combat aging-related diseases. Ageing Res Rev. 2021.Review
A review of nano-delivery's reach into age-related disease models. PubMed
18. Darmonkow A, et al. Advancements in curcuminoid formulations. Open Life Sci. 2025.Review
A recent update stressing how inconsistent analytical methods keep reported absorption numbers from being comparable. PubMed
19. Hatamipour M, Sahebkar A, Alavizadeh SH, et al. Novel nanomicelle formulation to enhance bioavailability and stability of curcuminoids. Iran J Basic Med Sci. 2019.Chemistry
Peer-reviewed physical characterization of a commercial nanomicelle, the transparency standard every "nano" brand should meet. PubMed Cited in this article as reference 17.

Domain C: Cyclodextrin--curcumin chemistry

20. Tønnesen HH, et al. Cyclodextrin complexation: solubility, chemical and photochemical stability. Int J Pharm. 2002.Chemistry
Foundational chemistry: cyclodextrin complexation raises curcumin's water solubility by orders of magnitude at mildly acidic pH while improving stability. PubMed
21. Wüpper S, et al. Cyclodextrins, natural compounds, and plant bioactives. Biomolecules. 2021.Review
Reviews cyclodextrins as food and pharmaceutical excipients; regulatory status and intake limits are specific to each cyclodextrin type, route, and jurisdiction. PubMed Cited in this article as reference 7.
22. Zeng Y, et al. Curcumin-loaded hydroxypropyl-β-cyclodextrin inclusion complex. Xenobiotica. 2022.Preclinical
An HP-β-CD complex sharply improved dissolution and modestly raised oral bioavailability in animals. PubMed
23. Li N, et al. Curcumin-HP-β-CD complex by cosolvency-lyophilization. Drug Dev Ind Pharm. 2018.Chemistry
Documents a clean 1:1 complex in solution but a finished powder where most curcumin sits outside a true inclusion complex, a caution against assuming uniform stoichiometry in solids. PubMed
24. Cutrignelli A, et al. Curcumin with sulfobutylether-β-cyclodextrin. J Pharm Sci. 2014.In vitro
An SBE-β-CD complex boosted solubility on the order of 180-fold while retaining activity in cell assays. PubMed
25. Zhang L, et al. Curcumin-cyclodextrin complexes enhanced anti-cancer effects. Environ Toxicol Pharmacol. 2016.In vitro
Cyclodextrin complexation increased curcumin's cellular uptake and measured activity, not just its solubility. PubMed
26. Li J, et al. Cyclodextrin encapsulation and intelligent release of curcumin. Polymers. 2022.Review
Explains that real cyclodextrin products are mixtures of free curcumin, complexes, and empty host, rather than a single pure species. PubMed
27. Yallapu MM, et al. β-Cyclodextrin-curcumin self-assembly enhances curcumin delivery in prostate cancer cells. Colloids Surf B. 2010.In vitro
Shows β-CD-curcumin self-assemblies improve cellular delivery of curcumin, the carrier family's core cell-level proof of principle. PubMed Cited in this article as reference 8.

Domain D: Measurement & bioavailability methodology

28. Luis PB, et al. Incomplete hydrolysis of curcumin conjugates by β-glucuronidase. Mol Nutr Food Res. 2020.Human PK
The standard enzymatic step used to read "total" curcumin underestimates it; adding sulfatase roughly doubled recovered curcumin, a direct hit to how bioavailability numbers are generated. PubMed
29. Vareed SK, et al. Pharmacokinetics of curcumin conjugate metabolites. Cancer Epidemiol Biomarkers Prev. 2008.Human PK
What circulates after an oral dose is overwhelmingly glucuronide and sulfate conjugates, with free curcumin rarely detectable. PubMed
30. Mahale J, et al. Plasma curcuminoids from dietary turmeric intake. Mol Nutr Food Res. 2018.Human PK
At food-relevant intakes, free curcumin was barely detectable while its glucuronide reached far higher levels. PubMed
31. Matthewman C, et al. Bioavailability and efficacy of 'free' curcuminoids from CGM formulation. Nutr Res Rev. 2023.Review
Argues the unconjugated "free" fraction is the meaningful one, but is formulation-affiliated, so not an independent authority. PubMed
32. Ireson C, et al. Characterization of curcumin metabolites and their ability to inhibit PGE2 production. Cancer Res. 2001.In vitro
Free curcumin suppressed a COX-2-driven inflammatory readout more strongly than several metabolites, one inactive, an early hint the free parent may matter most. PubMed
33. Ozawa H, et al. Curcumin β-D-glucuronide keeps high levels of free-form curcumin in blood. Biol Pharm Bull. 2017.Preclinical
In animals, injected glucuronide behaved as a circulating reservoir regenerating free curcumin, counter-evidence to treating conjugates as inert. PubMed
34. Girst G, et al. PK-driven evaluation of curcuminoid and metabolite antioxidant activity. Molecules. 2021.In vitro
Reduced metabolites like tetrahydrocurcumin keep meaningful antioxidant activity and are more stable than the parent. PubMed
35. Luca SV, et al. Bioactivity of dietary polyphenols: the role of metabolites. Crit Rev Food Sci Nutr. 2019.Review
Makes the general case that metabolites, not just parent compounds, can carry biological activity. PubMed

Domain E: Head-to-head formulation comparisons & brand pharmacokinetics (human)

36. Shoba G, et al. Influence of piperine on the pharmacokinetics of curcumin. Planta Med. 1998.Human PK
The single 1998 study behind the "2,000%" piperine claim: small, early-era analytics, and never independently replicated in the decades since. PubMed Cited in this article as reference 30.
37. Jäger R, et al. Comparative absorption of curcumin formulations. Nutr J. 2014.Human PK
A crossover pitting a phytosome, a turmeric-oil product, and a hydrophilic-carrier matrix against each other; the matrix showed by far the largest gain. No piperine arm. PubMed Cited in this article as reference 38.
38. Purpura M, et al. Innovative formulations of curcumin for improved oral bioavailability. Eur J Nutr. 2018.Human PK
Reports a large relative bioavailability advantage for a γ-cyclodextrin complex over standard extract, measured as total curcuminoids. PubMed Cited in this article as reference 15.
39. Stohs SJ, et al. Comparative PK of a novel highly bioavailable curcumin formulation. J Am Coll Nutr. 2018.Human PK
The small proprietary crossover behind the field's largest fold-figure (~522× dose-normalized, BioCurc), a headline number resting on one comparator. PubMed Cited in this article as reference 18.
40. Chung H, et al. Comparative pharmacokinetics of Theracurmin. Int J Clin Pharmacol Ther. 2021.Human PK
Human PK of a submicron dispersion showing tens-fold higher AUC than unformulated powder. PubMed Cited in this article as reference 23.
41. Pandaran Sudheeran S, et al. Curcumin with fenugreek dietary fiber. J Clin Psychopharmacol. 2016.Human PK
A small human study of a fenugreek-fiber matrix reporting large increases in free-curcuminoid absorption. PubMed
42. Flory S, et al. Increasing post-digestive solubility is the most successful strategy. Mol Nutr Food Res. 2021.Human PK
The rigorous eight-formulation crossover: post-digestive solubility, not carrier category, drives measured bioavailability; the piperine arm was ineffective; only conjugated curcumin was detected. PubMed Cited in this article as reference 32.
43. Hundshammer C, et al. Tetrahydrocurcumin after a γ-cyclodextrin curcumin complex. J Funct Foods. 2021. DOI (R16).Human PK
Industry study reporting large rises in total curcumin and tetrahydrocurcumin from a γ-CD complex. These are deconjugated figures, and a different carrier than β-CD. DOI Cited in this article as reference 16.
44. Kroon MAGM, et al. A pharmacokinetic study and critical reappraisal of curcumin formulations. iScience. 2025.Human PK
Independent five-formulation crossover: free curcumin stayed in the low-nanomolar range, piperine addition provided no benefit, and the authors argue claims should rest on unconjugated curcumin. PubMed Cited in this article as reference 21.
45. Schiborr C, et al. Oral bioavailability of curcumin from micronized powder and liquid micelles. Mol Nutr Food Res. 2014.Human PK
The NovaSOL trial: liquid micelles raised total-curcumin AUC ~185-fold over native powder in healthy adults, with notable sex differences. PubMed Cited in this article as reference 20.
46. Fança-Berthon P, et al. Pharmacokinetics of turmeric curcuminoids depends on formulation. J Nutr. 2021.Human PK
Five-formulation crossover in which a dried colloidal suspension and micellar form out-absorbed standard extract, and the piperine-curcuminoid combination did not differ from standard extract. PubMed Cited in this article as reference 33.
47. Thanawala S, et al. Water-dispersible turmeric extract vs. curcuminoids-piperine combination. Altern Ther Health Med. 2024.Human PK
A water-dispersible formulation matched the exposure of a curcuminoid+piperine product at a 10-fold lower dose of actives. PubMed Cited in this article as reference 34.
48. Antony B, et al. Human oral bioavailability of BCM-95CG. Indian J Pharm Sci. 2008.Human PK
A turmeric-essential-oil formulation absorbed ~6.9× better than plain curcumin, and ~6.3× better than a curcumin-lecithin-piperine formula. PubMed Cited in this article as reference 35.
49. Cuomo J, et al. Comparative absorption of curcuminoids and lecithin formulation (Meriva). J Nat Prod. 2011.Human PK
The phytosome PK study: a lecithin complex raised total curcuminoid absorption ~29-fold vs. unformulated mixture, measured as total, not free, curcuminoids. PubMed Cited in this article as reference 36.
50. Gota VS, et al. Solid lipid curcumin particle (Longvida) PK. J Agric Food Chem. 2010.Human PK
First-in-human PK of the solid-lipid-particle formulation in patients and volunteers. PubMed Cited in this article as reference 37.
51. Sunagawa Y, et al. Colloidal submicron-particle curcumin vs. other formulations. J Nutr Sci Vitaminol. 2015.Human PK
A direct three-way brand comparison (submicron dispersion vs. turmeric-oil vs. phospholipid formulations) showing the submicron dispersion absorbed best in that trial's conditions. PubMed Cited in this article as reference 44.
52. Briskey D, et al. Increased bioavailability of curcumin using LipiSperse dispersion. Eur J Nutr. 2019.Human PK
PK of a cold-water-dispersion coating technology showing roughly 2.5-fold higher plasma curcuminoids than standard extract. PubMed Cited in this article as reference 39.
53. Govindaraju R, et al. Curcumin in alginate-polysorbate 80 nanoparticles in healthy volunteers. Pharm Nanotechnol. 2019.Human PK
A 383 nm polysaccharide nanoparticle raised oral bioavailability ~5-fold in humans, one of the few experimental systems with human data. PubMed Cited in this article as reference 29.

Domain F: In vitro / mechanism of action (molecular targets)

54. Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin. Int J Biochem Cell Biol. 2009.Review
A heavily cited review mapping curcumin's modulation of transcription factors (notably NF-κB), cytokines, kinases, adhesion molecules, and redox enzymes. PubMed
55. Menon VP, Sudheer AR. Antioxidant and anti-inflammatory properties of curcumin. Adv Exp Med Biol. 2007.Review
Attributes curcumin's anti-inflammatory action largely to inhibition of COX-2, lipoxygenase, and iNOS, alongside free-radical scavenging. PubMed
56. Goel A, et al. Curcumin as "Curecumin": from kitchen to clinic. Biochem Pharmacol. 2008.Review
A landmark review compiling curcumin's molecular targets, transcription factors plus cell-cycle and survival proteins, tracing its path from spice to clinical candidate. PubMed
57. Gupta SC, et al. Multitargeting by curcumin as revealed by molecular interaction studies. Nat Prod Rep. 2011.Review
Documents, from direct biophysical binding studies, the many proteins curcumin physically interacts with, the molecular basis of its multitargeted pharmacology. PubMed
58. Kunnumakkara AB, et al. Curcumin, the golden nutraceutical. Br J Pharmacol. 2017.Review
Ties curcumin's suppression of NF-κB, STAT3, Nrf2, ROS, and COX-2 signaling to effects across chronic diseases, integrated with lessons from over 100 clinical trials. PubMed Cited in this article as reference 41.

Domain G: Preclinical studies of nanocurcumin formulations

59. Bisht S, et al. Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin"). J Nanobiotechnology. 2007.Preclinical
The paper that coined "nanocurcumin": a ~50 nm polymeric formulation that made curcumin water-dispersible and matched free curcumin's activity, including NF-κB blockade, in cancer cells. PubMed Cited in this article as reference 24.
60. Shaikh J, et al. Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold vs. piperine. Eur J Pharm Sci. 2009.Preclinical
The landmark delivery-vs-piperine result: PLGA nanoparticles beat curcumin+piperine by at least 9-fold on oral bioavailability in rats. PubMed Cited in this article as reference 28.
61. Maiti K, et al. Curcumin-phospholipid complex in rats. Int J Pharm. 2007.Preclinical
A phospholipid complex more than doubled peak curcumin levels and improved liver protection relative to free curcumin. PubMed
62. Xie X, et al. PLGA nanoparticles improve oral bioavailability of curcumin in rats. J Agric Food Chem. 2011.Preclinical
PLGA nanoparticles raised oral bioavailability several-fold in rats and water solubility hundreds-fold in vitro. PubMed Cited in this article as reference 27.
63. Zhongfa L, et al. Enhancement of curcumin oral absorption in mice. Cancer Chemother Pharmacol. 2011.Preclinical
An enhancer-containing formulation increased oral absorption in mice and characterized curcuminoid and reduced-metabolite exposure. PubMed
64. de Oliveira TV, et al. Antitumor effect of curcumin-loaded polymeric nanocapsules: systematic review and meta-analysis. Phytother Res. 2022.Preclinical
Meta-analysis of animal tumor studies: polymeric nanocapsules improved delivery and antitumor effect, strictly disease-model evidence. PubMed
65. Boroughani M, et al. Nanocurcumin in cancer treatment: comprehensive systematic review. Discov Oncol. 2024.Preclinical
A broad systematic review across cancer models summarizing consistent signals of improved delivery and activity. PubMed Cited in this article as reference 42.
66. Rahman MA, et al. Curcumin and nanocurcumin in glioblastoma. Nutrients. 2026.Review
A disease-focused review of nano-delivery aimed at pushing curcumin across the blood-brain barrier. PubMed
67. Greil R, et al. Phase 1 dose-escalation of liposomal curcumin (Lipocurc) in cancer patients. Cancer Chemother Pharmacol. 2018.Human PK
The furthest-advanced intravenous nanocurcumin program: dose-limiting effects defined the maximum tolerated dose in patients. PubMed Cited in this article as reference 26.

Domain H: Clinical studies & meta-analyses

68. Dhillon N, et al. Phase II trial of curcumin in advanced pancreatic cancer. Clin Cancer Res. 2008.Human PK
Observed biological signals in some patients despite very low circulating free curcumin; exposure and effect do not track simply. PubMed
69. Dehzad MJ, et al. Antioxidant and anti-inflammatory effects of curcumin/turmeric: GRADE-assessed meta-analysis. Cytokine. 2023.Meta-analysis
Curcumin lowers inflammatory and oxidative markers, the most consistent clinical domain, though with high between-study variability. PubMed
70. Kavyani Z, et al. Curcumin and inflammation, oxidative stress, endothelial function: meta-analysis of meta-analyses. Prostaglandins Other Lipid Mediat. 2024.Umbrella review
An umbrella synthesis reporting broadly favorable effects on inflammation, oxidative stress, and endothelial function. PubMed Cited in this article as reference 40.
71. Qin S, et al. Curcumin and oxidative stress markers. Nutr Res. 2018.Meta-analysis
Pooled trials indicate lower MDA and higher SOD. PubMed
72. Ghoflchi S, et al. Nanocurcumin in type 2 diabetes: meta-analysis. Endocrinol Diabetes Metab. 2026.Meta-analysis
Nanocurcumin trials improved antioxidant markers while several glycemic and lipid endpoints were unchanged. PubMed
73. Zheng X, et al. Curcumin and glycemic indices: meta-analysis of meta-analyses. Prostaglandins Other Lipid Mediat. 2024.Umbrella review
Umbrella review reporting glucose reductions, concentrated in metabolically ill populations. PubMed
74. Tabrizi R, et al. Curcumin and glycemic control and lipids in metabolic syndrome. Curr Pharm Des. 2018.Meta-analysis
Notably reported insulin rising even as glucose fell; pooled effects are not uniformly favorable. PubMed
75. Musazadeh V, et al. Curcumin and lipid profile: umbrella meta-analysis. Nutr Metab Cardiovasc Dis. 2022.Umbrella review
Reports curcumin can lower total cholesterol and triglycerides. PubMed
76. Saeedi F, et al. Curcumin and blood lipids: updated meta-analysis. Arch Physiol Biochem. 2020.Meta-analysis
The competing meta-analysis finding no significant effect on any lipid parameter; lipids are an inconsistent domain. PubMed
77. Zeng L, et al. Curcuma longa extract and curcumin in osteoarthritis. Biosci Rep. 2021.Meta-analysis
Pooled osteoarthritis trials found improved pain and function versus placebo. PubMed
78. Bideshki MV, et al. Curcumin in osteoarthritis: meta-analysis of meta-analyses. Phytother Res. 2024.Umbrella review
Umbrella review confirming a consistent symptom benefit in osteoarthritis populations. PubMed
79. Wang Z, et al. Curcumin for depressive symptoms: meta-analysis. J Affect Disord. 2020.Meta-analysis
A small antidepressant signal rated low-certainty; subclinical subgroup null (carries an erratum flagged for pre-reuse check). PubMed
80. Zhu LN, et al. Curcumin and cognitive function: meta-analysis. Phytother Res. 2018.Meta-analysis
Cognition trials were mixed, including an unfavorable Alzheimer's-subgroup signal. PubMed
81. Unhapipatpong C, et al. Curcumin and weight loss: umbrella review. Am J Clin Nutr. 2023.Umbrella review
Modest reductions in weight and waist measures; high overlap and risk of bias flagged in the underlying reviews. PubMed
82. Dehzad MJ, et al. Curcumin/turmeric and blood pressure, endothelial function. Clin Nutr ESPEN. 2023.Meta-analysis
Small systolic reduction and improved flow-mediated dilation, population-dependent. PubMed
83. Wilar G, et al. Nanocurcumin and metabolic syndrome: meta-analysis. Pharmacol Res. 2025.Meta-analysis
Nano-formulated curcumin improved several markers in metabolic-syndrome populations. PubMed
84. Ashtary-Larky D, et al. Nano-curcumin and cardiovascular risk factors: GRADE-assessed meta-analysis. Antioxidants. 2021.Meta-analysis
GRADE-rated synthesis of nanocurcumin's effects on cardiovascular risk markers in affected populations. PubMed
85. Sun Z, et al. Curcumin, anthropometric and cardiometabolic parameters: dose-effect meta-analysis. Crit Rev Food Sci Nutr. 2023.Meta-analysis
Reported larger effects for some nano subgroups, a subgroup signal, not a blanket advantage. PubMed
86. Hajimirzaei P, et al. The analgesic effect of curcumin and nano-curcumin in clinical and preclinical studies: systematic review and meta-analysis. Naunyn Schmiedebergs Arch Pharmacol. 2025.Meta-analysis
Pain meta-analysis across 30 clinical studies: benefit signals in every formulation category, wide overlap, high heterogeneity, no formulation winner. PubMed
87. Shi C, et al. Efficacy and safety of different curcumin formulations in osteoarthritis: an umbrella review of systematic reviews. Front Med (Lausanne). 2026.Umbrella review
Umbrella review of the osteoarthritis evidence: benefits reported across formulation-specific reviews, and a direct statement that head-to-head comparisons between formulation classes are missing from the field. PubMed

Domain I: Safety, interactions, and quality

88. EFSA ANS Panel. Refined exposure assessment for curcumin (E 100). EFSA J. 2014.Regulatory
The regulatory basis for the 0–3 mg/kg/day ADI for curcumin as a food additive, explicitly not a license for concentrated supplements. PubMed
89. Sahebkar A, Henrotin Y. Analgesic efficacy and safety of curcuminoids. Pain Med. 2016.Meta-analysis
Curcuminoids generally well tolerated short-term; mild GI effects most common. PubMed
90. Lombardi N, et al. Acute liver injury following turmeric use in Tuscany. Br J Clin Pharmacol. 2020.Case series
Often read as implicating high-bioavailability formulations, but on close reading a heterogeneous, largely piperine-containing case set. PubMed
91. Papke DJ, et al. Turmeric supplement-associated hepatitis: 11 cases. Histopathology. 2024.Case series
Implicated products were generally never chemically analyzed. PubMed
92. Góis FL, et al. Liver injury associated with irregular herbal products. Case Reports Hepatol. 2026.Case series
Chemical authentication traced "turmeric" injuries to mislabeling and adulteration, including a product containing essentially no curcumin. PubMed
93. Stati G, et al. Hepatotoxicity: a baseless accusation? Front Pharmacol. 2021.Case series
Advances the hypothesis that piperine co-formulation, rather than curcumin itself, underlies many liver-injury reports. PubMed
94. Bhardwaj RK, et al. Piperine inhibits human P-glycoprotein and CYP3A4. J Pharmacol Exp Ther. 2002.In vitro
The foundational demonstration of piperine's drug-interaction mechanism. PubMed Cited in this article as reference 31.
95. Lin F, et al. Piperine-CYP3A4 substrate interactions by PBPK modeling. Int J Mol Sci. 2024.Preclinical
A model predicting a piperine regimen could raise exposure to several CYP3A4-substrate drugs by roughly a third to a half. PubMed
96. Bahramsoltani R, et al. Pharmacokinetic interactions of curcuminoids with conventional drugs. J Ethnopharmacol. 2017.Review
Compiles potential interactions, drawn largely from in-vitro and animal data. PubMed
97. You H, et al. Labelling accuracy and adulteration: turmeric case study. Food Chem. 2021.Chemistry
Only 4 of 14 turmeric products matched natural turmeric's fingerprint; small sample, some industry-affiliated testing. PubMed Cited in this article as reference 43.
98. Halegoua-DeMarzio D, et al. Liver injury associated with turmeric: DILIN cases. Am J Med. 2022.Case series
Ten cases over twelve years, mostly overweight and often alcohol-using patients, tied to a genetic-susceptibility variant; turmeric chemically confirmed in tested products. PubMed
99. Forsyth JE, et al. Turmeric adulteration with lead chromate across South Asia. Sci Total Environ. 2024.Chemistry
Documented geographically concentrated lead-chromate adulteration, a contamination finding, not a U.S. prevalence estimate. PubMed
100. Ma C, et al. Dietary supplement adulteration: laboratory approaches. J Nat Prod. 2025.Review
Reviews identity/potency testing, supplier qualification, and third-party certificates as adulteration defenses. PubMed
101. Foxon F. How prevalent is liver injury attributed to turmeric? Am J Med. 2024. · DOI.Letter
A re-analysis arguing turmeric-attributed liver injury is very rare relative to the size of the using population. PubMed · DOI

References Cited in this Article

  1. Tayyem RF, et al. Curcumin content of turmeric and curry powders. Nutr Cancer. 2006. PubMed
  2. Hewlings SJ, Kalman DS. Curcumin: a review of its effects on human health. Foods. 2017. PubMed
  3. Sharma RA, et al. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res. 2004. PubMed
  4. Anand P, et al. Bioavailability of curcumin: problems and promises. Mol Pharm. 2007. PubMed
  5. Jacob S, et al. Advances in nanocarrier systems for overcoming formulation challenges of curcumin. Nanomaterials. 2024. PubMed
  6. Karthikeyan A, et al. Nanocurcumin: a promising candidate for therapeutic applications. Front Pharmacol. 2020. PubMed
  7. Wüpper S, et al. Cyclodextrins, natural compounds, and plant bioactives — a nutritional perspective. Biomolecules. 2021. PubMed
  8. Yallapu MM, et al. β-Cyclodextrin-curcumin self-assembly enhances curcumin delivery in prostate cancer cells. Colloids Surf B Biointerfaces. 2010. PubMed
  9. Sandur SK, et al. Curcumin, demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin and turmerones differentially regulate anti-inflammatory and anti-proliferative responses. Carcinogenesis. 2007. PubMed
  10. Sreejayan N, Rao MN. Free radical scavenging activity of curcuminoids. Arzneimittelforschung. 1996. PubMed
  11. Kalaycıoğlu Z, et al. Comparison of antioxidant, anticholinesterase, and antidiabetic activities of three curcuminoids isolated from Curcuma longa L. Nat Prod Res. 2017. PubMed
  12. Jayaprakasha GK, et al. Improved HPLC method for the determination of curcumin, demethoxycurcumin, and bisdemethoxycurcumin. J Agric Food Chem. 2002. PubMed
  13. Pan Y, et al. Separation of three curcuminoids by high-performance countercurrent chromatography. J Sep Sci. 2020. PubMed
  14. Qunol, "Why Qunol's Turmeric Supplement is Better" (manufacturer disclosure of gamma-cyclodextrin carrier). Link
  15. Purpura M, et al. Analysis of different innovative formulations of curcumin for improved relative oral bioavailability in human subjects. Eur J Nutr. 2018. PubMed
  16. Hundshammer C, et al. Enhanced metabolic bioavailability of tetrahydrocurcumin after oral supplementation of a γ-cyclodextrin curcumin complex. J Funct Foods. 2021. DOI (industry-authored)
  17. Hatamipour M, Sahebkar A, Alavizadeh SH, et al. Novel nanomicelle formulation to enhance bioavailability and stability of curcuminoids (SinaCurcumin®; ~10 nm micelles, 9.5 ± 0.1 nm by DLS). Iran J Basic Med Sci. 2019. PubMed
  18. Stohs SJ, et al. A comparative pharmacokinetic assessment of a novel highly bioavailable curcumin formulation with 95% curcumin. J Am Coll Nutr. 2018. PubMed
  19. Stohs SJ, et al. Highly bioavailable forms of curcumin and promising avenues for curcumin-based research and application. Molecules. 2020. PubMed
  20. Schiborr C, et al. The oral bioavailability of curcumin from micronized powder and liquid micelles is significantly increased in healthy humans. Mol Nutr Food Res. 2014. PubMed
  21. Kroon MAGM, et al. A pharmacokinetic study and critical reappraisal of curcumin formulations enhancing bioavailability. iScience. 2025. PubMed · DOI
  22. Sasaki H, et al. Innovative preparation of curcumin for improved oral bioavailability. Biol Pharm Bull. 2011. PubMed
  23. Chung H, et al. Comparative pharmacokinetics of Theracurmin in healthy adult subjects. Int J Clin Pharmacol Ther. 2021. PubMed
  24. Bisht S, et al. Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin"): a novel strategy for human cancer therapy. J Nanobiotechnology. 2007. PubMed
  25. Storka A, et al. Safety, tolerability and pharmacokinetics of liposomal curcumin in healthy humans. Int J Clin Pharmacol Ther. 2015. PubMed
  26. Greil R, et al. A phase 1 dose-escalation study on the safety, tolerability and activity of liposomal curcumin (Lipocurc) in patients with locally advanced or metastatic cancer. Cancer Chemother Pharmacol. 2018. PubMed
  27. Xie X, et al. PLGA nanoparticles improve the oral bioavailability of curcumin in rats. J Agric Food Chem. 2011. PubMed
  28. Shaikh J, et al. Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. Eur J Pharm Sci. 2009. PubMed
  29. Govindaraju R, et al. Enhanced water dispersibility of curcumin encapsulated in alginate-polysorbate 80 nanoparticles and bioavailability in healthy human volunteers. Pharm Nanotechnol. 2019. PubMed
  30. Shoba G, et al. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med. 1998. PubMed
  31. Bhardwaj RK, et al. Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4. J Pharmacol Exp Ther. 2002. PubMed
  32. Flory S, et al. Increasing post-digestive solubility of curcumin is the most successful strategy to improve its oral bioavailability. Mol Nutr Food Res. 2021. PubMed
  33. Fança-Berthon P, et al. Pharmacokinetics of a single dose of turmeric curcuminoids depends on formulation: results of a randomized crossover trial in healthy adults. J Nutr. 2021. PubMed
  34. Thanawala S, et al. Comparative pharmacokinetics of a water-dispersible turmeric extract versus curcuminoids-piperine combination. Altern Ther Health Med. 2024. PubMed
  35. Antony B, et al. A pilot cross-over study to evaluate human oral bioavailability of BCM-95CG (Biocurcumax). Indian J Pharm Sci. 2008. PubMed
  36. Cuomo J, et al. Comparative absorption of a standardized curcuminoid mixture and its lecithin formulation (Meriva). J Nat Prod. 2011. PubMed
  37. Gota VS, et al. Safety and pharmacokinetics of a solid lipid curcumin particle formulation (Longvida) in osteosarcoma patients and healthy volunteers. J Agric Food Chem. 2010. PubMed
  38. Jäger R, et al. Comparative absorption of curcumin formulations. Nutr J. 2014. PubMed
  39. Briskey D, et al. Increased bioavailability of curcumin using a novel dispersion technology system (LipiSperse). Eur J Nutr. 2019. PubMed
  40. Kavyani Z, et al. The effects of curcumin supplementation on inflammation, oxidative stress and endothelial function: a meta-analysis of meta-analyses. Prostaglandins Other Lipid Mediat. 2024. PubMed
  41. Kunnumakkara AB, et al. Curcumin, the golden nutraceutical: multitargeting for multiple chronic diseases. Br J Pharmacol. 2017. PubMed
  42. Boroughani M, et al. Nanocurcumin in cancer treatment: a comprehensive systematic review. Discov Oncol. 2024. PubMed
  43. You H, et al. Analytical strategies to determine labelling accuracy and economically-motivated adulteration of "natural" dietary supplements: turmeric case study. Food Chem. 2021. PubMed
  44. Sunagawa Y, et al. Colloidal submicron-particle curcumin exhibits high absorption efficiency: a double-blind, 3-way crossover study. J Nutr Sci Vitaminol. 2015. PubMed
  45. Helli B, et al. Curcumin nanomicelle improves lipid profile, stress oxidative factors and inflammatory markers in patients undergoing coronary elective angioplasty: a randomized clinical trial. Endocr Metab Immune Disord Drug Targets. 2021. PubMed
  46. Grafeneder J, et al. Micellar curcumin: pharmacokinetics and effects on inflammation markers and PCSK-9: a randomized controlled trial. Mol Nutr Food Res. 2022. PubMed
  47. Zhang Y, et al. Efficacy of curcumin, its derivatives and delivery systems in MASLD animal models: a three-level meta-analysis. J Ethnopharmacol. 2026. PubMed
  48. Sasaki H, et al. Innovative preparation of curcumin for improved oral bioavailability. Biol Pharm Bull. 2011. PubMed
  49. Kheiripour N, et al. Hepatoprotective effects of curcumin and nanocurcumin against paraquat-induced liver injury in rats. J Biochem Mol Toxicol. 2021. PubMed
  50. Sankar P, et al. Comparison of the protective effect of curcumin and nanocurcumin against arsenic-induced genotoxicity in rats. Mol Biol Rep. 2014. PubMed
  51. Sarawi WS, et al. Curcumin and nano-curcumin mitigate copper neurotoxicity by modulating oxidative stress and inflammation. Molecules. 2021. PubMed
  52. Sataei-Mokhtari S, et al. Comparative effects of curcumin and nano-curcumin on spexin and metabolic parameters in type 2 diabetic rats. J Diabetes Metab Disord. 2025. PubMed
  53. Dende C, et al. Nanocurcumin is superior to native curcumin in preventing degenerative changes in experimental cerebral malaria. Sci Rep. 2017. PubMed
  54. Kazemi-Darabadi S, et al. Curcumin and nanomicelle curcumin effects on skeletal muscle wound healing in rats. Bull Emerg Trauma. 2019. PubMed
  55. Sadraei MR, et al. Effect of curcumin and nano-curcumin on sperm parameters in varicocele-induced rats. Andrologia. 2022. PubMed
  56. Ghasemzadeh Rahbardar M, et al. Comparative effects of curcumin and nanocurcumin against inhaled paraquat toxicity in rats. Iran J Basic Med Sci. 2025. PubMed
  57. Elbassiouni FE, et al. Comparative study between curcumin and curcumin-loaded PLGA nanoparticles in a colon carcinogenesis model. Nanomaterials. 2022. PubMed
  58. Volak LP, et al. Effect of a herbal extract containing curcumin and piperine on midazolam, flurbiprofen and paracetamol (acetaminophen) pharmacokinetics in healthy volunteers. Br J Clin Pharmacol. 2013. PubMed
  59. Vajdi M, et al. Curcumin supplementation effect on liver enzymes in patients with nonalcoholic fatty liver disease: a GRADE-assessed systematic review and dose-response meta-analysis of randomized controlled trials. Nutr Rev. 2025. PubMed

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Back to blog